Ospemifene Size:Contact [email protected] for quotation InChi: InChI=1S/C41H84O21/c1-43-4-5-45-8-9-47-12-13-49-16-17-51-20-21-53-24-25-55-28-29-57-32-33-59-36-37-61-40-41-62-39-38-60-35-34-58-31-30-56-27-26-54-23-22-52-19-18-50-15-14-48-11-10-46-7-6-44-3-2-42/h42H

InChi: InChI=1S/C41H84O21/c1-43-4-5-45-8-9-47-12-13-49-16-17-51-20-21-53-24-25-55-28-29-57-32-33-59-36-37-61-40-41-62-39-38-60-35-34-58-31-30-56-27-26-54-23-22-52-19-18-50-15-14-48-11-10-46-7-6-44-3-2-42/h42H

A-867744 normalized gating deficits

Auristatin F inhibits tubulin polymerization

MHRA (3 September 2012) and TGA (26 July 2012) approval for use as a treatment for renal cell carcinoma

and action as a kappa opioid receptor and u-receptor agonist

Ospemifene Size:Contact [email protected] for quotation InChi: InChI=1S/C41H84O21/c1-43-4-5-45-8-9-47-12-13-49-16-17-51-20-21-53-24-25-55-28-29-57-32-33-59-36-37-61-40-41-62-39-38-60-35-34-58-31-30-56-27-26-54-23-22-52-19-18-50-15-14-48-11-10-46-7-6-44-3-2-42/h42HOspemifene is a non estrogen selective estrogen receptor modulator (SERM), with Kis of 380 and 410 nM for estrogen receptor (ER) and ER, respectively. Ospemifene can be used for the research of vaginal atrophy and breast cancer. Product information CAS Number: 128607 22 7 Molecular Weight: 378. 89 Formula: C24H23ClO2 Chemical Name: 2 {4 [(1Z) 4 chloro 1,2 diphenylbut 1 en 1 yl]phenoxy}ethan 1 ol Smiles: OCCOC1C=CC(=CC=1) C(=C( CCCl)\C1C=CC=CC=1)